Loading...

GNPX GENPREX INC Company Mergers 8-K Filing

GNPR

GNPX

GENPREX INC

(GNPX)

2025 8-K

Nasdaq Compliance Update

Share Offering Update

New Clinical Trial Site

Patent Approval Announced

Patent Grant Update

Stock Offering Agreement

Positive Preclinical Data

Securities Offering

Positive Data Announcement

Stock Split Update

Compliance Update

Delisting Alert

Patent Allowance News

Equity Incentive Plan

Stockholder Updates

Product Expansion

Product Expansion

Equity Offerings

Stock Compliance

Product Expansion

Clinical Trials

License Agreement Update

Nasdaq Compliance Notice

Clinical Trial Update

Investor Presentation

Clinical Trial Update

License Agreement

Nasdaq Compliance Issue

Nasdaq Compliance

Research Collaboration

Clinical Trial Update

Nasdaq Compliance Notice

Subsidiary Formation

Press Release & Stockholder...

Amendment and Separation Ag...

Management Changes

Securities Purchase Agreement

Business Updates and Positi...

Compliance Regained

Resignation and Clinical St...

Resignation of Director

Reverse Stock Split

Business Updates and Plans

Special Meeting of Stockhol...

Agreement for At The Market...

Bylaws Amendment

Engagement of New Independe...

Equity Offerings

Annual Meeting and Clinical...

Clinical Trial Update

Accountant Resignation

Securities Purchase Agreement

Salary Adjustments, Bonuses...

Clinical Trial Update

Exclusive License Agreement...

External Links:

On August 18, 2025, Genprex, Inc. announced that it has received patent allowances for its lead drug Reqorsa® to be used with PD-L1 and PD-1 antibodies, expiring in 2037, as part of its ongoing clinical trials for small cell lung cancer.

AI Assistant

GENPREX INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.